Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Diabetes
•
Endocrinology
Outside of Teplizumab, what therapies do you recommend for preserving beta cell function in patients with early stage type 1 diabetes mellitus?
Is there strong data for the use of Verapamil, Metformin, Amylin, GLP 1 R agonists or Januvia?
Related Questions
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
When managing patients with suspected MASLD, what specific criteria or findings would prompt you to refer them to hepatology?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
What is the typical timeline for remission of autoimmune hypoglycemia?
How do you adjust your management strategy to address the unique needs of anuric end-stage kidney disease patients when treating diabetic ketoacidosis?
Do patients with advanced chronic kidney disease tend to have falsely high HbA1c or falsely low HbA1c levels?
Which patients would benefit most from teplizumab therapy to delay the onset of T1DM?
Is GLP-1 therapy a viable treatment option for a patient with Type 2 Diabetes complicated by atherosclerotic heart disease and cholelithiasis?
How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?